매출 성장 + 마진 확대 + FCF 양수
Positive매출이 +5.7% 성장하면서 영업이익률이 1.2%에서 4.2%로 확대되었다. FCF도 양수를 유지하여 질적 성장이 확인된다.
Evidence
매출 YoY +5.7%영업이익률 1.2%→4.2%FCF 12,271
DAE HWA Pharmaceutical
A067080 · KOSDAQ₩8,880+11.14%
2026-08-03 closeDAE HWA Pharmaceutical — pricey right now, or cheap? And what signals are flashing today?
Open the exact grade & valuation bands with Pro →Loading chart…
Close
AI Insight
Why these signals fired — only backtest-proven edge, told honestly
Strong-buy signal — the real recordrecord · not a prediction
Not this one stock, but every strong-buy pick we actually published (Korea market). When this stock flashes the signal, it is treated by the same rule.(as of 2026-08-03)
Last 30 sessions
648 picks
Next-day win rate
49.2%
Avg next-day
-0.17%
vs market
+0.72%p
Beat the market on 62.1% of picks (each pick vs its own day’s market average).
Recent publish days (next-day win rate)
07-31 0%07-30 66.7%07-29 0%07-28 45%07-27 20%07-25 36.4%07-21 55.6%07-20 53.8%07-16 53.3%07-15 50%07-14 71.4%07-13 31.2%
This stock has not flashed this signal recently — the record above is the signal’s own, not this stock’s.
Entry is the latest close at publish time; next-day is the following close. “Market” is the equal-weighted average of every stock in the same market that day; delisted names are excluded from both. Fees, taxes and slippage are not included. An observed record over a short window, not a pre-registered backtest. Not investment advice.
Valuation Grades
Relative to 295 건강관리 peers · not investment advice
Valuation in its own history
PER 311.09 · PBR 2.3 — own history (2003-02~) percentiles 26/100 · 69/100
PER26/100
PBR69/100
Higher indicates lower valuation relative to its history (based on earnings and book yields).
Earnings percentiles can fluctuate for cyclical companies (including loss periods), so the book basis is shown alongside. Companies with large share buybacks can have structurally high PBR. Factual information, not investment advice.
Annual dividend
Split-adjusted annual DPS history and available grade axes
Paid 23 consecutive years · Raised 0 consecutive years · Yield 1.69% (based on 2025 payment of 150원) · 3-year growth +0.0%
Per-share amount adjusted for splits and capital reductions · Factual information, not investment advice.
Financial safety
Reference indicatorAs of 2024Distress zoneFinancial-metric reference signal
Altman Z'' zoneZ'' -0.40
Distress
Grey
Safe
- Altman Z''
- -0.40
- Beneish M-Score
- -2.78
- Sloan accrual
- -2.72%
No statistical flag
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Why has this company moved this way?
Auditable observations with the original numeric evidence.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
9/9Strong
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score9/9
Profitability
- Positive ROAPass
- Positive OCFPass
- Improving ΔROAPass
- Accruals (OCF > net income)Pass
Leverage & liquidity
- Lower debtPass
- Higher current ratioPass
- No new sharesPass
Efficiency
- Higher gross marginPass
- Higher asset turnoverPass
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Forensic signals
Anomaly and structural signals observed in the financial statements.
Margin trendWarning
영업외손익 급변 (영업이익 대비 46% 규모 변동) — 일회성 손익 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.
Factual information, not investment advice.
Industry structure
KRAs of 2026-08-03건강관리
This stock is in 건강관리: revenue rank 83 of 290, share 0.2%.
83 / 2900.2%revenue share
Who dominates this industry?
- 1삼성바이오로직스7.3%
- 2셀트리온5.7%
- 3녹십자홀딩스3.5%
- 4유한양행3.3%
- 5대웅3.1%
- 6대화제약0.2%
Concentration
DistributedCR3 16.6%HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.
Polarization
Winner-take-all deepeningConsistentPolarization measures industry gaps and structure, not valuation, forecast, or investment advice.
Margin lens
- IQR%p
- 31.61
- Direction
- 확대
- Level
- 넓음
- Years
- 7
Value lens
- P90/P10
- 14
- Median P/B
- 1.47
- Level
- 넓음
- n
- 269
Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)
Factual information, not investment advice.
Risk sensitivity — adverse assumptions
Metric changes under stated assumptions; not a forecast or investment advice.
Base metrics
- Operating margin
- 4.2%
- Interest coverage
- 1.1x
- Return on equity (ROE)
- 0.7%
Operating margin −5pp
Operating lossInterest coverageBase 1.1x adverse case -0.2x
Return on equity (ROE)Base 0.7% adverse case -9.3%
Revenue −15%
Interest coverage riskInterest coverageBase 1.1x adverse case 1x
Return on equity (ROE)Base 0.7% adverse case -0.2%
Interest rate +2pp
Interest coverage riskInterest coverageBase 1.1x adverse case 0.8x
Return on equity (ROE)Base 0.7% adverse case -2.7%
Interest coverage limit
Current margin 0.5ppInterest coverage limit at an operating margin of 3.7%
Interest expense coverage threshold
Key suppliers · Annual report
Annual reportDART · 2026-03-23Suppliers disclosed by the company in its 2026-03-23 annual report.
Suppliers without disclosed amount
리독스바이오하이플하이팜해피콜
Financials at a glance
DAE HWA Pharmaceutical's latest results and balance sheet. The bars track the last three periods.
Who held it · filings
Filed recordA historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.
US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.
5%+ major-holding disclosures
- 고준진28.42%2026-02-06 · 증감 0.00%p
- 김수지26.94%2025-02-07 · 증감 0.00%p
Recent filings
DAE HWA Pharmaceutical's latest filings on Korea's DART. Open a headline for a reference summary and the original.
Source: DART (Korea electronic disclosure)
Like these rules? Run them automatically.
Quantus turns rules like these into backtests and automated trading — same team, free to start.
Quantus Signal · live data · not investment advice · Privacy Policy